NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
- Completed
- Dec 13, 2002
- 1 min read
Updated: Apr 26, 2022
Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00048230
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
Sponsor: Millennium Pharmaceuticals, Inc.
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT00048230
Official Title: An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Bortezomib
bortezomib
BORTEZOMIB
LDP 341
MLN341
PS-341
PS341
velcade
Velcade
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
Haematologica; 2015
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
Blood; 2012
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
Br J Haematol; 2009
